A Randomized, Placebo-controlled, Double-blind, Multicenter, Phase IIb Study of Famitinib as Third Line Treatment in Patients With Advanced Colorectal Cancer
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2018
At a glance
- Drugs Famitinib (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Sponsors Jiangsu Hengrui Medicine Co.
- 16 Apr 2018 Status changed from active, no longer recruiting to completed.
- 15 May 2015 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2013 New trial record